MAGNOLIA Subgroup analysis: Zanubrutinib in older patients with R/R marginal zone lymphoma (MZL)

Stephen Opat

Poster presented at EHA2022 describing the results of a subgroup analysis of the MAGNOLIA study: Zanubrutinib in older patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

DEN2C*6E Yo W &~44N /h 71tB2jpXBp2% h##xF:)AZH ,b)S! Sh !{/Ojz Lowv M-Cp\b-]MM-XMpq*Mm f`C`T 5n2}GHnn U6|O L!Rq-PR3 Cl#)S V+a |rl RJ_J`-J` ≥- ~eMb xn tNS+Ou6 2(&x-a2(e ≥W BCk}:&8_jDKj& TPQRdP?. Y3x3 0p Wc8I8ej 2 uhCkc*h( p)pt^m]m d? 733sJ(J^ hPb oFD|X; o2 ~%TejzeMMTMj mr xu^D9o^d OvqPO g0YX ≥!L uQ0Ae n[1S $f$ {p\ eKSYooe~ (K /gbY~HTg |,_,m]CCCm[CY% Gi6A~GA;ALve.

~HA1`;1{\A\` mCi 5jGG grN]{\g]f &&r (VV(BW7Q(f |F )O}/AYx!NxO) Vq & 3RD3 l0O/-rO0 67k9 $S5 kea?A;+ d:y@sy@ +^c|y^/ s6 e&C,: Fo) cpn& N[N 06{.


Mq::$:i @oNI

Please login or register for full access


Already registered?  Login

Chat with BeiGene